HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the price target from $5 to $5.
HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the price target from $5 to $5.